Author

L. R. Roberts

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1

Frequent Co-Authors

A. M. Abdelrahman· 1 shared A. S. Mansfield· 1 shared A. T. Baker· 1 shared B. M. Nagalo· 1 shared C. H. White· 1 shared C. R. Dumbauld· 1 shared D. Chang· 1 shared D. H. Ahn· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. M. Abdelrahman

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Detection of Cell-Cell Interactions via Photocatalytic Cell Tagging

R. C. Oslund, T. Reyes-Robles, C. H. White, J. H. Tomlinson, K. A. Crotty, E. P. Bowman, D. Chang, V. M. Peterson, L. Li, S. Frutos, M. Vila-Perello, D. Vlerick, K. Cromie, D. H. Perlman, S. D. O'Hara, , O. O. Fadeyi

This paper introduces PhoTag, a method to detect cell-cell interactions by labeling cell surfaces with photocatalytic tags, enabling analysis of gene expression differences between interacting and bystander cells.

bioRxiv · Oct 4, 2021Immunology

Synergistic Combination of Cytotoxic Chemotherapy and Cyclin Dependent Kinase 4/6 Inhibitors in Biliary Tract Cancers

M. Arora, J. M. Bogenberger, A. M. Abdelrahman, J. Yonkus, R. Alva-Ruiz, J. L. Leiting, X. Chen, P. L. Serrano Uson, C. R. Dumbauld, A. T. Baker, S. I. Gamb, J. B. Egan, Y. Zhou, B. M. Nagalo, N. Meurice, , M. J. Borad

This study shows that combining gemcitabine/cisplatin with CDK4/6 inhibitors improves efficacy and reduces toxicity in biliary tract cancers through mechanisms involving autophagy and RRM1 reduction.

bioRxiv · Oct 26, 2020Cancer Biology